Telomir Pharmaceuticals
TELO1.2306.96% ( +0.080 )
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Overview: Telomir Pharmaceuticals(TELO) the EBIT is -1.041 M (+52.4%);the EPS is -0.0288 (+60.65%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
EBIT
-0.00B52.40%
----
----
EPS
-0.028860.65%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf